Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
30 août 2021 09h15 HE
|
Protagenic Therapeutics, Inc.
Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic...
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
17 août 2021 07h45 HE
|
Protagenic Therapeutics, Inc.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Three High Profile Publications Support the Potential of Protagenic Therapeutics’s Synthetic TCAP to Treat Stress-Related Psychological Disorders
11 juin 2018 10h15 HE
|
Protagenic Therapeutics, Inc.
Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology NEW YORK,...